Firms
MQB Partners
MQB Partners is a Wellington, New Zealand healthcare investment partnership operated by MQB Partners Limited. It invests in a concentrated portfolio of healthcare companies approaching clinical, regulatory or commercial inflection points. The partnership targets medical devices, robotics, artificial intelligence, novel therapeutics and clinically significant digital health. Its partners commit substantial personal capital before inviting aligned investors, including family offices and specialist co-investors, to participate. Its active ownership model combines clinical and commercial judgement with governance, financing strategy, R&D, execution and exit preparation. The current four-partner team comprises Marko Bogoievski, managing partner Caroline Quay, scientist Scott McPhee and physician Ken Chin. Its official portfolio identifies neuroscience drug developer Cerevance and robotic airway-management company Spiro Robotics. Cerevance issuer announcements independently confirm MQB participation in the April2024 SeriesB-1 extension and May2026 SeriesC. The website’s legal terms identify MQB Partners Limited as the operator; the brand is not presumed to be the direct legal subscriber for every managed investment vehicle. No publicly verified LP fund cash close or fund size is asserted. Prior Morrison & Co/Infratil assets under management and historical company exits belong to the partners’ earlier careers and are not MQB capital raised.
- Founded
- —
- Type
- Venture capital
Funds0
No funds on record yet.
Team
Operations and support
 Caroline QuayManaging Partner |
 Ken ChinPartner |
 Marko BogoievskiPartner |
 Scott McPheePartner |
Co-investing
Cerevance$47M · 2024-04-25
Bioluminescence Ventures- Cerevance$47M · 2024-04-25
Dementia Discovery Fund- Cerevance$20M · 2026-05-12
LifeRock Ventures- Cerevance$47M · 2024-04-25
UPMC Enterprises- Cerevance$20M · 2026-05-12
